Sarepta Therapeutics: Q4 Earnings Insights
Portfolio Pulse from Benzinga Insights
Sarepta Therapeutics (NASDAQ:SRPT) reported Q4 earnings with an EPS of $0.82, significantly beating the estimate of $0.01 and marking an 8100.0% increase. Revenue rose by $138.35 million from the same period last year. The company has a history of beating EPS estimates, which previously led to a 2.0% share price increase the following day.
February 28, 2024 | 9:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sarepta Therapeutics reported a significant Q4 earnings beat with an EPS of $0.82 against an estimate of $0.01, and a substantial year-over-year revenue increase.
The substantial beat on both EPS and revenue expectations, combined with the company's history of positive market reactions to earnings beats, suggests a likely positive short-term impact on SRPT's stock price.
CONFIDENCE 90
IMPORTANCE 95
RELEVANCE 100